DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. OCRP Research Highlights/News
  3. 2013 Ovarian Cancer Research Program

NEWS RELEASE

Released: April 19, 2013

Defense Health Program
Department of Defense Ovarian Cancer Research Program
Funding Opportunities for Fiscal Year 2013

The Fiscal Year 2013 (FY13) Defense Appropriations Act provides $20 million (M) to the Department of Defense Ovarian Cancer Research Program (OCRP) to support innovative, high-impact ovarian cancer research. The OCRP is administered by the US Army Medical Research and Materiel Command (USAMRMC) through the Office of Congressionally Directed Medical Research Programs (CDMRP).

The OCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY13 OCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in May and June 2013. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.

Mechanism Eligibility Key Mechanism Elements Funding
Clinical Translational Leverage Award Investigators at or above the level of Assistant Professor (or equivalent).
  • Supports leveraging of existing human-based ovarian cancer resources in translational research.
  • Research must address high-impact ideas or unmet needs in ovarian cancer.
  • Examples include: a correlative study for a clinical trial; clinical annotation of an available human biorepository; infrastructure and administrative expense to make an existing biorepository available to a wider community of translational scientists.
  • Preliminary data are required.
  • Clinical trials are not allowed.
  • Preproposal is required; application submission is by invitation only.
  • Maximum funding of $250,000 for direct costs plus indirect costs).
  • Period of performance not to exceed 2 years.
Ovarian Cancer Academy Award Early-Career investigator must be within the first 3 years of his/her first faculty position (or equivalent) at the time of award. The first faculty position (or equivalent) may be either tenure-track or non-tenure track.

Designated Mentor must be an independent ovarian cancer researcher and at the same institution as the Early-Career Investigator.
  • Supports the addition of new early-career investigators to the unique, interactive virtual academy that will provide intensive mentoring, national networking, and a peer group for junior faculty.
  • Designated Mentor who is an experienced ovarian cancer researcher with ovarian cancer funding is required for Early-Career Investigators.
  • Preliminary data are required.
  • Institutional match of $50,000 per year is required.
  • Preproposal is required; application submission is by invitation only.
  • Maximum funding of $725,000 for direct costs (plus indirect costs).
  • Period of performance not to exceed 5 years.
Resource Development Award Investigators at all levels.
  • Supports either the development of a new resource(s) or increasing the utility of existing human-based resource(s).
  • Resource must address a high-impact opportunity or an unmet need in ovarian cancer research.
  • Maximum funding of $400,000 for direct costs (plus indirect costs).
  • Period of performance not to exceed 2 years.
Pilot Award Investigators at or above the postdoctoral level (or equivalent).
  • Supports conceptually innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer research forward.
  • Innovation and Impact are important review criteria
  • Preliminary data are not required, but allowed.
  • Clinical trials are not allowed.
  • Preproposal is required; application submission is by invitation only.
  • Maximum funding of $225,000 for direct costs with additional $75,000 for optional nested Teal Postdoctoral Scholar (plus indirect costs).
  • Period of performance not to exceed 2 years.
Teal Innovator Award Investigators at the level of Professor (or equivalent), and recognized in his/her field.
  • Supports a visionary individual from any field principally outside of, but not exclusive of, ovarian cancer to focus their creativity, innovation, and leadership on ovarian cancer research.
  • Provides opportunity to pursue novel, visionary, high-risk ideas that could ultimately lead to the elimination of ovarian cancer.
  • Preproposal is required; application submission is by invitation only.
  • Maximum funding of $2.5M for direct costs (plus indirect costs).
  • Period of performance not to exceed 5 years.

All applications must conform to the final program announcements and application instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

A pre-application is required and must be submitted through the CDMRP eReceipt website (http://cdmrp.org) prior to the pre-application deadline. Applications must be submitted through the federal government's single-entry portal, Grants.gov. Submission deadlines are not available until the program announcements are released. Requests for email notification of the program announcements release may be sent to help@cdmrp.org. For more information about the OCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).

Point of Contact: